{"id":812391,"date":"2022-08-05T07:27:49","date_gmt":"2022-08-05T05:27:49","guid":{"rendered":"https:\/\/15.161.165.86\/non-categorizzato\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/"},"modified":"2022-08-05T07:27:49","modified_gmt":"2022-08-05T05:27:49","slug":"bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/","title":{"rendered":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress"},"content":{"rendered":"- beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 -\n\n\n- eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 -\n\n\n- Ended quarter with $218M in restricted cash, cash and cash equivalents\n\n\nand marketable securities -\n\nSOMERVILLE, Mass--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or the \u201cCompany\u201d) today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.\n\n\n\n\u201cThe second quarter marked significant progress for bluebird bio and a precedent-setting moment for the field of gene therapy,\u201d said Andrew Obenshain, chief executive officer, bluebird bio. \u201cWith the FDA advisory
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

– beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 – – eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 – – Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities – SOMERVILLE, Mass–(BUSINESS WIRE)–bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-812391","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nbluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"- beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 - - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T05:27:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress\",\"datePublished\":\"2022-08-05T05:27:49+00:00\",\"dateModified\":\"2022-08-05T05:27:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\"},\"wordCount\":2182,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\",\"name\":\"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-08-05T05:27:49+00:00\",\"dateModified\":\"2022-08-05T05:27:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/","og_locale":"en_US","og_type":"article","og_title":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","og_description":"- beti-cel for beta-thalassemia PDUFA goal date is set for August 19, 2022 - - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (\u201cbluebird bio\u201d or […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/","og_site_name":"BeBeez","article_published_time":"2022-08-05T05:27:49+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/"},"author":{"name":"","@id":""},"headline":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress","datePublished":"2022-08-05T05:27:49+00:00","dateModified":"2022-08-05T05:27:49+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/"},"wordCount":2182,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/","name":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-08-05T05:27:49+00:00","dateModified":"2022-08-05T05:27:49+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/bluebird-bio-reports-second-quarter-2022-financial-results-and-highlights-operational-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812391","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=812391"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/812391\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=812391"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=812391"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=812391"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=812391"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=812391"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}